Oramed Pharmaceuticals Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Oramed Pharmaceuticals şirketinin kazançlarının yıllık 104.1% oranında düşmesi, yıllık gelirinin ise yıllık 256.9% oranında artması bekleniyor. EPS'nin yıllık 104.4% oranında düşüşmesi bekleniyor.

Anahtar bilgiler

-104.1%

Kazanç büyüme oranı

-104.4%

EPS büyüme oranı

Pharmaceuticals kazanç büyümesi	19.7%
Gelir büyüme oranı	256.9%
Gelecekteki özkaynak getirisi	n/a
Analist kapsamı	Low
Son güncelleme	02 Dec 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

Here's Why We're Not Too Worried About Oramed Pharmaceuticals' (NASDAQ:ORMP) Cash Burn Situation

Aug 24

Oramed Pharmaceuticals (NASDAQ:ORMP) Is In A Good Position To Deliver On Growth Plans

May 03

Companies Like Oramed Pharmaceuticals (NASDAQ:ORMP) Are In A Position To Invest In Growth

Dec 22

Companies Like Oramed Pharmaceuticals (NASDAQ:ORMP) Are In A Position To Invest In Growth

Feb 23

Oramed And The Hurdles Of Developing Oral Insulin

Dec 23

Here's Why We're Not Too Worried About Oramed Pharmaceuticals' (NASDAQ:ORMP) Cash Burn Situation

Nov 02

Oramed: Prospects Still Remain Despite Merck-Ridgeback's Progress

Oct 04

We Think Shareholders Will Probably Be Generous With Oramed Pharmaceuticals Inc.'s (NASDAQ:ORMP) CEO Compensation

Aug 24

Oramed Pharmaceuticals (NASDAQ:ORMP) Is In A Good Position To Deliver On Growth Plans

Jul 21

Oramed reaches 50% enrollment in late-stage oral insulin study

Jun 08

Oramed Pharmaceuticals (NASDAQ:ORMP) Is In A Good Position To Deliver On Growth Plans

Apr 06

Kazanç ve Gelir Büyüme Tahminleri

NasdaqCM:ORMP - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2025	1	-8	N/A	N/A	2
12/31/2024	N/A	-10	N/A	N/A	2
9/30/2024	N/A	4	-8	-8	N/A
6/30/2024	N/A	21	-2	-2	N/A
3/31/2024	1	10	-6	-6	N/A
12/31/2023	1	6	-11	-10	N/A
9/30/2023	2	-16	-17	-17	N/A
6/30/2023	3	-20	-19	-18	N/A
3/31/2023	3	-30	-25	-24	N/A
12/31/2022	3	-37	-28	-28	N/A
9/30/2022	3	-46	-39	-39	N/A
6/30/2022	3	-46	-43	-43	N/A
3/31/2022	3	-40	-39	-39	N/A
12/31/2021	3	-35	-33	-33	N/A
11/30/2021	3	-25	-22	-22	N/A
8/31/2021	3	-22	-22	-21	N/A
5/31/2021	3	-18	-18	-17	N/A
2/28/2021	3	-15	-16	-15	N/A
12/31/2020	3	-22	-26	-25	N/A
11/30/2020	3	-15	-16	-16	N/A
8/31/2020	3	-12	-13	-12	N/A
5/31/2020	3	-11	-13	-13	N/A
2/29/2020	3	-13	-14	-14	N/A
11/30/2019	3	-13	-12	-12	N/A
8/31/2019	3	-14	-13	-13	N/A
5/31/2019	3	-15	-14	-14	N/A
2/28/2019	3	-15	-14	-14	N/A
11/30/2018	3	-14	-16	-16	N/A
8/31/2018	2	-13	N/A	-15	N/A
5/31/2018	2	-12	N/A	-12	N/A
2/28/2018	2	-10	N/A	-11	N/A
11/30/2017	2	-10	N/A	-10	N/A
8/31/2017	2	-10	N/A	-6	N/A
5/31/2017	2	-13	N/A	3	N/A
2/28/2017	2	-13	N/A	3	N/A
11/30/2016	1	-11	N/A	8	N/A
8/31/2016	1	-11	N/A	5	N/A
5/31/2016	0	-8	N/A	-3	N/A
2/29/2016	0	-8	N/A	-2	N/A
11/30/2015	N/A	-8	N/A	-6	N/A
8/31/2015	N/A	-7	N/A	-5	N/A
5/31/2015	N/A	-7	N/A	-5	N/A
2/28/2015	N/A	-7	N/A	-5	N/A
11/30/2014	N/A	-6	N/A	-5	N/A
8/31/2014	N/A	-6	N/A	-4	N/A
5/31/2014	N/A	-5	N/A	-4	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: ORMP şirketinin kazançlarının önümüzdeki 3 yıl içinde düşmesi öngörülüyor (yılda -104.1% ).

Kazançlar ve Piyasa: ORMP şirketinin kazançlarının önümüzdeki 3 yıl içinde düşmesi öngörülüyor (yılda -104.1% ).

Yüksek Büyüme Kazançları: ORMP şirketinin kazançlarının önümüzdeki 3 yıl içinde düşmesi öngörülüyor.

Gelir ve Pazar: ORMP şirketinin gelirinin (yıllık 256.9% ) US pazarından (yıllık 9% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: ORMP şirketinin gelirinin (yıllık 256.9% ) yıllık 20% dan daha hızlı büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: ORMP 'un Özsermaye Getirisi'nin 3 yıl içinde yüksek olmasının öngörülüp öngörülmediğini belirlemek için yeterli veri yok

Büyüyen şirketleri keşfedin

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2025/01/02 11:44
Gün Sonu Hisse Fiyatı	2025/01/02 00:00
Kazançlar	2024/09/30
Yıllık Kazançlar	2023/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.

Analist Kaynakları

Oramed Pharmaceuticals Inc. 8 Bu analistlerden 2, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Andrew D'Silva	B. Riley Securities, Inc.
Edward Nash	Canaccord Genuity
Charles Duncan	Cantor Fitzgerald & Co.

Oramed Pharmaceuticals Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Consensus revenue estimates decrease by 50%

Consensus revenue estimates increase by 15%

Consensus EPS estimates fall by 50%

Consensus EPS estimates upgraded to US$0.34 loss

Consensus EPS estimates fall by 13%

Consensus EPS estimates upgraded to US$0.35 loss

Recent updates

New minor risk - Market cap size

Investor sentiment improves as stock rises 21%

Oramed Pharmaceuticals Inc. (NasdaqCM:ORMP) announces an Equity Buyback for $20 million worth of its shares.

Oramed Pharmaceuticals Inc. (NasdaqCM:ORMP) announces an Equity Buyback for $20 million worth of its shares.

Oramed Pharmaceuticals Inc., Annual General Meeting, Aug 01, 2024

Oramed Pharmaceuticals Inc. Appoints Mr. Avraham Gabay as Treasurer and Secretary, Effective as of June 18, 2024

Consensus revenue estimates decrease by 50%

Consensus revenue estimates increase by 15%

New major risk - Revenue and earnings growth

First quarter 2024 earnings released: EPS: US$0.038 (vs US$0.085 loss in 1Q 2023)

New minor risk - Market cap size

Oramed Pharmaceuticals Inc. has filed a Follow-on Equity Offering in the amount of $75 million.

Full year 2023 earnings: EPS and revenues exceed analyst expectations

New minor risk - Share price stability

Consensus EPS estimates fall by 50%

Insufficient new directors

Oramed Pharmaceuticals Inc. Appoints Daniel Aghion as Director, Effective January 1, 2024

Third quarter 2023 earnings released: US$0.08 loss per share (vs US$0.18 loss in 3Q 2022)

New minor risk - Market cap size

Here's Why We're Not Too Worried About Oramed Pharmaceuticals' (NASDAQ:ORMP) Cash Burn Situation

Consensus EPS estimates upgraded to US$0.34 loss

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Oramed Pharmaceuticals Inc. (NasdaqCM:ORMP) entered into a Stalking Horse Stock Purchase Term Sheet to acquire a 40.17% stake in Scilex Holding Company (NasdaqCM:SCLX) from Sorrento Therapeutics, Inc. (OTCPK:SRNE.Q) for approximately $110 million.

Oramed Pharmaceuticals Inc., Annual General Meeting, Jul 13, 2023

Oramed Pharmaceuticals Inc., Annual General Meeting, Jul 13, 2023

Consensus EPS estimates fall by 13%

Consensus EPS estimates upgraded to US$0.35 loss

Price target decreased by 82% to US$2.40

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Oramed Pharmaceuticals (NASDAQ:ORMP) Is In A Good Position To Deliver On Growth Plans

President recently bought US$201k worth of stock

Independent Director recently bought US$142k worth of stock

Consensus EPS estimates upgraded to US$0.59 loss

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased by 23% to US$15.16

Price target decreased to US$21.67

Oramed Pharmaceuticals Inc. Announces Top-Line Results from Phase 3 Trial of ORMD-0801 for the Treatment of Type 2 Diabetes

Oramed Pharmaceuticals Inc. Granted U.S. Combination Therapy Patent for Oral Glp-1 & Insulin for the Treatment of Diabetes

Companies Like Oramed Pharmaceuticals (NASDAQ:ORMP) Are In A Position To Invest In Growth

Price target decreased to US$28.67

Oramed Announces Additional Positive Safety and Efficacy Data from Its Phase 2 Clinical Trial of ORMD-0801 for NASH

Consensus forecasts updated

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

High number of new and inexperienced directors

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Oramed: Oral Insulin For Type 2 Diabetes May Become A Reality

Oramed Pharmaceuticals Inc. Reports Positive Top-Line Results from Phase 2 Nash Trial with its ORMD-0801, Oral Insulin Candidate

Oramed to hand Korean rights for insulin capsule

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Oramed Reaches 50% Enrollment in Its Second Phase 3 Oral Insulin Trial

High number of new and inexperienced directors

Oramed to report early-stage trial data for oral COVID-19 shot in 3Q

Is Oramed Pharmaceuticals (NASDAQ:ORMP) In A Good Position To Invest In Growth?

Oramed Pharmaceuticals Inc., Annual General Meeting, Jun 30, 2022

Oramed Pharmaceuticals Inc. Appoints Anne Peters to Its Scientific Advisory Board

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Oramed Pharmaceuticals Inc. Completes Patient Enrollment in Pivotal Phase 3 Oral Insulin Study Ora-D-013-1

Price target increased to US$32.50

Oramed And Oral Insulin: Can This Small Company Really Do It?

Oramed Pharmaceuticals Inc. Grants NASH Patent in Europe

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Independent Chairman of the Board recently sold US$94k worth of stock

Consensus forecasts updated

Companies Like Oramed Pharmaceuticals (NASDAQ:ORMP) Are In A Position To Invest In Growth

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus forecasts updated

Oramed And The Hurdles Of Developing Oral Insulin

Oramed Subsidiary Oravax Announces First Participant Enrolled in Phase 1 Oral Covid-19 Vaccine Trial in South Africa

Full year 2021 earnings: EPS and revenues miss analyst expectations